Analyst consensus rating
Innoviva Analyst Rating: Buy
Direct answer
Innoviva's consensus rating is Buy.
5 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $34.80.
Forecast evidence checked November 14, 2026.
Get free Innoviva email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $19.03
- Average price target
- $34.80
- High price target
- $46.00
- Low price target
- $18.00
- Low target gap
- -5.4%
- Target upside
- +82.9%
- High target gap
- +141.7%
- Target range width
- 147.1%
- Consensus rating
- Buy
- Analysts
- 5
- Evidence date
- November 14, 2026
- Valid through
- November 21, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Innoviva?
Innoviva has a verified Buy consensus. The same dataset has an average price target of $34.80.
How far are Innoviva's low and high targets from the recorded price?
The low target implies -5.4%, while the high target implies +141.7%.
How many analysts are included in Innoviva's consensus?
The verified consensus includes 5 analysts.
How is Innoviva's target upside or downside calculated?
The average target of $34.80 is divided by the recorded price of $19.03, then one is subtracted to produce +82.9%. This does not guarantee a future return.
When was Innoviva's analyst forecast verified?
The data was verified on 2026-11-14. The dataset is valid through 2026-11-21.